PDLLA
Poly-D,L-lactic acid (PDLLA) is a polylactic-acid material derived from both D- and L-lactide forms. In aesthetic injectables, the useful distinction is not simply “PDLLA versus PLLA.” Particle architecture, excipients, added HA, product presentation, and intended use can differ substantially within PDLLA itself.
At a glance
Section titled “At a glance”| Question | Practical answer |
|---|---|
| What is being injected? | Product-specific biodegradable PDLLA particles |
| Is HA always included? | No. Some products are PDLLA-based; others are explicitly PDLLA + HA hybrids |
| Immediate effect | Depends on the full formulation and prepared suspension |
| Initial products | AestheFill; Juvelook family |
| Main caution | Do not transfer particle, preparation, or safety claims from one PDLLA brand to another |
Two product architectures in the first map
Section titled “Two product architectures in the first map”AestheFill
Section titled “AestheFill”REGEN Biotech describes AestheFill as an injectable PDLLA product for improvement of facial wrinkles and folds. Its official page identifies PDLLA as the material and warns that availability and intended use vary by country (REGEN Biotech 🔗).
Juvelook family
Section titled “Juvelook family”VAIM’s Korean product page identifies Juvelook presentations as combinations of PDLLA and HA. The listed quantities differ across the family: for example, the page lists 42.5 mg PDLLA plus 7.5 mg HA for Juvelook and 170 mg PDLLA plus 30 mg HA for Juvelook Volume (Juvelook product information 🔗).
That makes Juvelook more than a generic PDLLA entry. The HA component, total content, particle characteristics, preparation, and intended product role must remain visible.
Product map
Section titled “Product map”| Product | Material structure | Hybrid component | First company relationship |
|---|---|---|---|
| AestheFill | PDLLA-based injectable particles | Not presented as the same PDLLA + HA format as Juvelook | REGEN Biotech |
| Juvelook | PDLLA particles | HA, with product-specific listed quantity | VAIM |
| Juvelook Volume | PDLLA particles with a higher listed product content than Juvelook | HA, with product-specific listed quantity | VAIM |
This table identifies product architecture, not clinical equivalence or recommended substitution.
Why PDLLA is not simply “faster PLLA”
Section titled “Why PDLLA is not simply “faster PLLA””PLLA and PDLLA differ in polymer structure, but clinical behavior cannot be predicted from stereochemistry alone. Commercial products add further variables:
- particle size distribution
- particle shape and porosity
- molecular characteristics
- excipients and HA
- preparation method
- concentration and presentation
- placement and treatment objective
Claims that a porous or reticulated particle is easier, safer, faster-degrading, or less likely to form nodules require evidence for the exact product and endpoint. Manufacturer descriptions can establish how a product is designed; they do not independently establish comparative clinical superiority.
Immediate and delayed effects
Section titled “Immediate and delayed effects”For a hybrid PDLLA + HA product, avoid describing the clinical sequence as if the components do the same job. The prepared product may produce early hydration or physical correction while the PDLLA component is discussed in relation to a later tissue response.
For PDLLA products without the same HA formulation, early presentation may differ. “PDLLA” alone does not answer the immediate-effect question.
Preparation and placement
Section titled “Preparation and placement”Preparation must be recorded by exact brand and presentation. Do not infer that:
- AestheFill and Juvelook use the same liquid volume
- Juvelook and Juvelook Volume share placement guidance
- a smaller listed product content means the same product at a lower dose
- a regional name maps perfectly to a Korean presentation
Approved wording can also be broader or narrower than common clinical discussion. VAIM’s Korean product page describes temporary improvement of adult facial wrinkles through physical restoration; it should not be rewritten into approval for every frequently discussed skin-quality or anatomical use.
Safety interpretation
Section titled “Safety interpretation”PDLLA products remain particulate injectables unless a product-specific source establishes otherwise. Product familiarity does not remove the need to consider vascular anatomy, sterile technique, depth, distribution, inflammatory reactions, nodules, infection, and delayed events.
Related materials
Section titled “Related materials”- Nodules and delayed reactions keeps hybrid components and infection assessment visible.
- Vascular and visual emergencies explains why an HA component does not create a complete reversal pathway.
- PLLA vs PDLLA explains what the material names support—and what they do not.
- PLLA provides the closest material-family comparison but not a substitute protocol.
- CaHA separates a mineral microsphere component from its gel carrier.
- PCL reinforces why physical form must remain visible alongside chemistry.